Secondary analyses showed that median OS was significantly longer for patients receiving masitinib followed by post-progression addition of sunitinib when compared against patients treated directly with sunitinib in second-line [ hazard ratio ( HR ) = 0.27 , 95 % CI 0.09-0 .85 , P = 0.016 ] .